LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.

    Strong, James S / Vos, Elvira L / Mcintyre, Caitlin A / Chou, Joanne F / Gonen, Mithat / Tang, Laura H / Soares, Kevin C / Balachandran, Vinod P / Kingham, T Peter / D'Angelica, Michael I / Jarnagin, William R / Drebin, Jeffrey / Kunstman, John W / Allen, Peter J / Wei, Alice C

    The American surgeon

    2021  Volume 88, Issue 6, Page(s) 1153–1158

    Abstract: Background: Neutrophil-to-lymphocyte ratio (NLR) has been reported as prognostic in pancreatic ductal adenocarcinoma (PDAC). Data about NLR changes during neoadjuvant therapy (NAT) and its relationship with pathological tumor response and survival are ... ...

    Abstract Background: Neutrophil-to-lymphocyte ratio (NLR) has been reported as prognostic in pancreatic ductal adenocarcinoma (PDAC). Data about NLR changes during neoadjuvant therapy (NAT) and its relationship with pathological tumor response and survival are lacking.
    Methods: Pancreatic ductal adenocarcinoma patients with NAT followed by resection between 2009 and 2015 were identified from a prospective database. Neutrophil-to-lymphocyte ratio was collected prior to NAT (baseline), on chemotherapy (prior to cycle 3), and prior to surgery. Baseline NLR, and changes in NLR between baseline and on chemotherapy (delta 1) and between baseline and surgery (delta 2) were compared with pathologic response (<90% and ≥90% defined as poor and good), overall (OS), and disease-free survival (DFS) using Wilcoxon rank-sum and Cox proportional hazard models.
    Results: Of 93 patients, 17% had good pathological response. Median (interquartile range) NLR at baseline, third cycle, and surgery were 2.7 (2.0-3.7), 2.5 (1.9-4.1), and 3.1 (2.1-5.3), respectively. Median change in NLR from baseline to third cycle was .06 (
    Discussion: Neutrophil-to-lymphocyte ratio increased after NAT, but a significant association between NLR and pathological response, OS, and DFS in resected PDAC patients was not observed.
    MeSH term(s) Adenocarcinoma/pathology ; Carcinoma, Pancreatic Ductal/surgery ; Humans ; Lymphocytes ; Neoadjuvant Therapy ; Neutrophils ; Pancreatic Neoplasms/surgery ; Prognosis ; Retrospective Studies ; Pancreatic Neoplasms
    Language English
    Publishing date 2021-01-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 202465-2
    ISSN 1555-9823 ; 0003-1348
    ISSN (online) 1555-9823
    ISSN 0003-1348
    DOI 10.1177/0003134821989050
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

    Pulvirenti, Alessandra / Rao, Deepthi / Mcintyre, Caitlin A / Gonen, Mithat / Tang, Laura H / Klimstra, David S / Fleisher, Martin / Ramanathan, Lakshmi V / Reidy-Lagunes, Diane / Allen, Peter J

    HPB : the official journal of the International Hepato Pancreato Biliary Association

    2018  Volume 21, Issue 5, Page(s) 612–618

    Abstract: Background: Serum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs.: ... ...

    Abstract Background: Serum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs.
    Methods: Patients with well-differentiated PanNET and a baseline CgA measurement, between 2011 and 2016 were reviewed. The diagnostic value was determined by comparing CgA values from patients with PanNETs to those with other pancreatic neoplasms and healthy controls. The Kaplan-Meier method was used to investigate the CgA prognostic significance.
    Results: Ninety-nine patients met inclusion criteria. As a diagnostic marker, CgA had a sensitivity of 66%, specificity of 95%, and overall accuracy of 71%. The use of PPIs was associated with a higher CgA level (p = 0.015). When excluding patients on PPIs, CgA accuracy in distinguishing PanNETs from other pancreatic neoplasms was 66%, the sensitivity and specificity were 60% and 75% respectively. Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival.
    Conclusion: CgA has a limited role as a diagnostic biomarker for well-differentiated PanNETs. An elevated CgA level may have prognostic value but its role should be further investigated with respect to other known pathological factors.
    MeSH term(s) Biomarkers, Tumor/blood ; Case-Control Studies ; Chromogranin A/blood ; Female ; Humans ; Male ; Middle Aged ; Neuroendocrine Tumors/blood ; Pancreatic Neoplasms/blood ; Prognosis ; Sensitivity and Specificity
    Chemical Substances Biomarkers, Tumor ; Chromogranin A
    Language English
    Publishing date 2018-10-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2131251-5
    ISSN 1477-2574 ; 1365-182X
    ISSN (online) 1477-2574
    ISSN 1365-182X
    DOI 10.1016/j.hpb.2018.09.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top